Opus Genetics, Inc.
IRD · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.01 | -0.00 | 0.34 |
| FCF Yield | -17.20% | -27.03% | -19.80% | -14.98% |
| EV / EBITDA | -3.06 | -1.52 | -0.74 | 0.32 |
| Quality | ||||
| ROIC | -48.21% | -41.52% | -148.74% | -23.35% |
| Gross Margin | 0.00% | 100.00% | 99.77% | 100.00% |
| Cash Conversion Ratio | 0.35 | 1.38 | 1.10 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -36.52% | -30.16% | -31.02% | -34.90% |
| Free Cash Flow Growth | -14.18% | -20.92% | -44.99% | 29.65% |
| Safety | ||||
| Net Debt / EBITDA | 3.64 | 3.37 | 0.33 | 4.87 |
| Interest Coverage | -254.46 | -7.24 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 142.93 | -16,725.15 | -28,211.25 | 77.39 |